News & Updates

Show Multimedia Only

Can fasting and a no-sugar diet alleviate long COVID symptoms?

19 Aug 2025 by

In a crossover trial evaluating the effect of two intermittent fasting (IF) regimens on long COVID (LC) symptoms, a daily 16-h fast with water-only fast and a no-sugar diet fared better than a daily 14-h time-restricted eating (TRE) regimen for mitigating long COVID symptoms.

Can fasting and a no-sugar diet alleviate long COVID symptoms?

19 Aug 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

19 Aug 2025

New drug applications approved by US FDA as of 1-15 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

19 Aug 2025

Hormone therapy use has no bearing on severe COVID-19 outcomes

17 Aug 2025

A recent study suggests that the use of hormone therapy does not contribute to increased women with severe symptoms of COVID-19.

Hormone therapy use has no bearing on severe COVID-19 outcomes

17 Aug 2025

Advancing collaboration in COVID-19 care

16 Aug 2025

Held in June 2025 in Singapore, the Pfizer COVID-CONNECT Masterclass convened international experts to discuss the evolving challenges of COVID-19. Co-chaired by Dr Asok Kurup and Dr Luke Moore, this event assessed the ongoing global impact of the disease and explored evidence-based strategies across the patient journey from early identification to effective treatment.

Advancing collaboration in COVID-19 care

16 Aug 2025

Multimorbidity, frailty up risk of COPD readmission

15 Aug 2025 by

Frailty and multimorbidity may increase the likelihood of being readmitted within 30 days following an index admmission among patients with chronic obstructive pulmonary disease (COPD), reveals a Singapore study.

Multimorbidity, frailty up risk of COPD readmission

15 Aug 2025

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

At the recent COVID-CONNECT Masterclass, an expert-led session explored where COVID-19 stands among common viral infections today. In a non-promotional symposium supported by Pfizer, infectious disease specialist Dr Leong Hoe Nam, Mount Elizabeth Hospital Novena, Singapore, discussed strategies for managing viral infections and surge preparedness. Complementing this, Professor David Strain from the University of Exeter Medical School, UK highlighted the enduring burden of long COVID.

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

13 Aug 2025 by

The IMPROVE trial shows the feasibility and safety of 1-month isoniazid and rifapentine (1HP) in an inpatient setting as tuberculosis preventive therapy (TPT) in patients with advanced HIV disease (AHD) and cryptococcal meningitis (CM).

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

13 Aug 2025

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

The growing range of treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) has made first-line decisions more complex and more critical. Patients are increasingly more aware of new and different treatment options and are seeking therapies that align with their personal values. As survival outcomes continue to improve, shared decision-making (SDM) plays a vital role in individualising care by integrating clinical evidence with what matters most to each individual. This article explores how SDM can support patient-centred care, drawing on insights from Professor James Yang and patient advocate Mark Brooke.

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

Aspiration pneumonia outcomes better with ampicillin–sulbactam vs cephalosporins

05 Aug 2025

In the treatment of patients with aspiration pneumonia, ampicillin–sulbactam helps reduce in-hospital mortality and prevent Clostridioides difficile infection compared with cephalosporins, according to a study from Japan.

Aspiration pneumonia outcomes better with ampicillin–sulbactam vs cephalosporins

05 Aug 2025

Nirmatrelvir–ritonavir combo not better than ritonavir alone in adults with long COVID

03 Aug 2025

For individuals with long COVID, treatment with nirmatrelvir plus ritonavir does not appear to yield improvements in health outcomes when compared with ritonavir alone, according to a phase II study.

Nirmatrelvir–ritonavir combo not better than ritonavir alone in adults with long COVID

03 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

Can fasting and a no-sugar diet alleviate long COVID symptoms?

Can fasting and a no-sugar diet alleviate long COVID symptoms?

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

Hormone therapy use has no bearing on severe COVID-19 outcomes

Hormone therapy use has no bearing on severe COVID-19 outcomes

Advancing collaboration in COVID-19 care

Advancing collaboration in COVID-19 care

Multimorbidity, frailty up risk of COPD readmission

Multimorbidity, frailty up risk of COPD readmission

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Aspiration pneumonia outcomes better with ampicillin–sulbactam vs cephalosporins

Aspiration pneumonia outcomes better with ampicillin–sulbactam vs cephalosporins

Nirmatrelvir–ritonavir combo not better than ritonavir alone in adults with long COVID

Nirmatrelvir–ritonavir combo not better than ritonavir alone in adults with long COVID